NCT03035058View on ClinicalTrials.gov

Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel Disease

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 28, 2017

Primary Completion Date

September 30, 2020

Study Completion Date

January 31, 2021

Conditions
Primary Sclerosing CholangitisInflammatory Bowel Disease
Interventions
DRUG

Vedolizumab

Vedolizumab intravenous infusion

DRUG

Placebo

Placebo

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT03035058 - Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel Disease | Biotech Hunter | Biotech Hunter